VSTM vs XENE Stock Comparison

VSTM currently leads XENE in this stock comparison, with AIQ scores of 60 vs 49. The clearest difference is momentum, while XENE has the stronger quality profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 11 points
VSTM
Healthcare
vs
XENE
Healthcare
VSTM
Verastem, Inc.
Leads
Price
$8.18
Day move
-3.08%
AIQ Score
60/100
Best edge
Momentum
Sector
Healthcare
XENE
Xenon Pharmaceuticals Inc.
Price
$40.48
Day move
-1.26%
AIQ Score
49/100
Best edge
Quality
Sector
Healthcare

What is the main difference between VSTM and XENE?

VSTM leads the current stock comparison as Verastem, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Verastem, Inc. vs Xenon Pharmaceuticals Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 7/10

VSTM leads

VSTM leads by 11 AIQ points, primarily on Momentum.

Competitive: 4 of 5 evidence groups support VSTM, and its current signal state is conflicted.

Evidence agreement: 4 of 5Comparison trend: Stable
VSTM

Verastem, Inc.

Leads
AIQ Score
60/100
AIQ Edge Score
6/10
XENE

Xenon Pharmaceuticals Inc.

AIQ Score
49/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors VSTM over XENE, 60 versus 49 as of Nov 15, 2026. VSTM's advantage is driven primarily by stronger momentum, while XENE holds the stronger quality profile. VSTM also shows the weaker technical structure relative to its 50-day moving average. 4 of 5 covered evidence groups favor VSTM today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. VSTM lead: Stable — the AIQ differential has held near 11 points over 30 sessions.

Compare Verastem, Inc. and Xenon Pharmaceuticals Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

VSTM
-78.4%
XENE
+32.2%

Price return comparison

Growth of $10,000, price only

VSTM $2,164 · XENE $13,216

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare VSTM and XENE against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

VSTM advantage
0
XENE advantage
  • Momentum89 vs 33
    VSTM +56
  • Quality42 vs 68
    XENE +26
  • Risk Resilience36 vs 49
    XENE +13

4 of 5 evidence groups favor VSTM. VSTM’s edge is concentrated in momentum; XENE keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

VSTM0 AIQ

Largest factor move: Momentum -2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 4 active signals are unchanged.

XENE0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

VSTM's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — VSTM and XENE both carry a full feed there.

The central trade-off

VSTM (Verastem, Inc.): the stronger current systematic profile, led by momentum.

XENE (Xenon Pharmaceuticals Inc.): the counter-case, on quality, risk resilience.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

VSTM

VSTM on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

XENE

XENE on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

VSTM

VSTM on the Momentum factor, by 56 points.

Lower downside

XENE

XENE on Risk Resilience, by 13 points.

Analyst upside

VSTM

VSTM on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureVSTMXENENote
Implied upside to target+126.2%+67.6%VSTM has more room
Target dispersion+48.6%+64.8%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1018Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 5 covered evidence groups favor VSTM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreVSTM60 vs 49
FundamentalsVSTMTTM ROE -7.4% vs -9.6%
ValuationNot coveredNot covered
TechnicalsVSTMPrice vs 50-day -3.6% vs -1.6%; vs 200-day 29.9% vs -22.6%
Risk ResilienceXENERisk Resilience 36 vs 49
Analyst expectationsVSTMTarget upside 126.2% vs 67.6%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of VSTM and XENE and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is moderate at 11 points.
  • 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on VSTM.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

VSTM lead: Stable — the AIQ differential has held near 11 points over 30 sessions.

May 27VSTM leads above the line · XENE leads belowNov 13
Today
VSTM +11
60 vs 49
7 sessions ago
VSTM +11
60 vs 49
30 sessions ago
VSTM +11
57 vs 46
90 sessions ago
XENE +22
51 vs 73

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

VSTMConflicted

2 bullish / 1 bearish / 1 neutral, conflicted

Only VSTM

  • Golden Cross Active — bullish, trend, long horizon (34.78%)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
XENE

0 bullish / 3 bearish / 2 neutral

Only XENE

  • Death Cross Active — bearish, trend, long horizon (27.10%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Downtrend Structure Active — bearish, trend, long horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

VSTM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

VSTMNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -3.08%, AIQ 0 points).

XENENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1XENE closes the Momentum gap — currently 56 points behind, the largest single contributor to VSTM's edge.
  2. 2XENE's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3VSTM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

VSTM leads on balance
MetricVSTMXENE
Revenue growth (YoY)-40.1%0%
EPS growth (YoY)-111.4%0%
Gross margin86.1%0%
Operating margin-193.7%0%
Return on equity (TTM)-7.4%-9.6%
Debt to equity12.090.01

Performance

Split across windows
MetricVSTMXENE
1 week (5 sessions)-2.7%3.3%
1 month (20 sessions)-5.4%20.9%
3 months (63 sessions)13.9%-35.1%
6 months (126 sessions)89.4%-25.6%
Year to date6%-9.7%
1 year (252 sessions)-3.9%2%

Technicals

VSTM has the stronger structure
MetricVSTMXENE
RSI (14)41.654.9
ADX (14)28.324
Price vs 50-day-3.6%-1.6%
Price vs 200-day29.9%-22.6%
Volatility (1M, annualized)72.4%38%

Risk

XENE is the more resilient
MetricVSTMXENE
Beta0.890.86
Sharpe ratio0.320.27
Sortino ratio0.490.48
Max drawdown-67.6%-52.8%
Current drawdown-23.1%-43%
Annualized volatility74.2%68.1%
Value at risk (95%)-7.2%-3.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, VSTM or XENE?

On the Algovestiq AIQ Score, VSTM is the stronger of the two as of Nov 15, 2026, scoring 60 against XENE's 49. The edge comes from momentum. XENE is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is VSTM or XENE the better buy right now?

VSTM carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor VSTM over XENE?

The composite weights Quality, Value, Momentum and Risk Resilience. VSTM leads Momentum by 56 points; XENE leads Quality by 26 points; XENE leads Risk Resilience by 13 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, VSTM or XENE?

Analyst price targets imply +126.2% upside for VSTM and +67.6% for XENE, so the Street currently favors VSTM. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, VSTM or XENE?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, VSTM or XENE?

XENE on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, VSTM or XENE?

VSTM on the Momentum factor, by 56 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, VSTM or XENE?

XENE is the more resilient of the two, so the other name carries the higher downside risk. XENE on Risk Resilience, by 13 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is VSTM more profitable than XENE?

VSTM leads on the comparable margin measures — gross margin 86.1% vs 0%; operating margin -193.7% vs 0%; ttm roe -7.4% vs -9.6%.

Is VSTM's lead over XENE getting stronger or weaker?

VSTM lead: Stable — the AIQ differential has held near 11 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the VSTM vs XENE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XENE closes the Momentum gap — currently 56 points behind, the largest single contributor to VSTM's edge; XENE's Death Cross Active resolves — a bearish trend rule currently active against it; VSTM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about VSTM and XENE?

VSTM: 2 bullish / 1 bearish / 1 neutral, conflicted. XENE: 0 bullish / 3 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on VSTM is Golden Cross Active (bullish, long horizon). On XENE it is Death Cross Active (bearish, long horizon).

Compare VSTM and XENE with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.